Skip to content
Precision for Medicine
Press Release

FDA Veteran Paz Vellanki, MD, joins Precision to become one of 3 ex-FDA oncology leaders supporting clients

false
Blog

The Precision Blog

100% sourced from leading minds on the front lines of research

Recent and Featured Posts

View all articles
  • Clinical Research Insights

    All Clinical Research Articles
    • Read: Clinical AI at Scale: Why Trust Matters More Than Speed Clinical AI at Scale: Why Trust Matters More Than Speed

      Clinical Trials

      Clinical AI at Scale: Why Trust Matters More Than Speed

      |
        has third author: false, (SizeLimitingPyMap: {main={hs_id=219402396746, hs_child_table_id=0, hs_updated_at=1787057935787, hs_published_at=1787135938204, description=Zulfat Kapadia is a Statistical Programmer with a scientist's heart and a programmer's precision, bringing over 11 years of experience in clinical data analytics. She currently works as a Statistical Programmer at Precision for Medicine, focusing on clinical data transformations and safety analytics. She is a SAS-certified Statistical Programmer with strong expertise in CDISC standards (SDTM and ADaM), turning raw clinical data into clean, submission-ready datasets and TLFs (Tables, Listings, and Figures). Her journey began with an M.Sc. in Microbiology from Gujarat University, followed by years as a Research Associate, where she worked hands-on with method development, validation, and LC-MS/MS analysis in GLP-regulated labs, including navigating regulatory audits. She later moved into SAS programming at Cognizant, building the technical foundation for her current specialization. A resourceful team player, she continues expanding her expertise across clinical and pharmaceutical domain., avatar=Image{width=1024,height=1536,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Zulfat%20Headshot.jpg',altText='Zulfat Headshot',fileId=219402357006}, lastname=Kapadia, hs_initial_published_at=1786648737451, hs_created_by_user_id=65712240, hs_created_at=1786648684030, hs_is_edited=false, hs_deleted_at=0, name=Zulfat, job=Statistical Programmer, slug=zulfat-kapadia, hs_updated_by_user_id=92535535}, second={hs_id=219402396744, hs_child_table_id=0, hs_updated_at=1786648683717, hs_published_at=1787135938204, description=As Principal Statistical Programmer, Shakila plays a key role in leading statistical programming activities for clinical development programs at Precision for Medicine. She has extensive experience managing study deliverables, supporting regulatory submissions, implementing CDISC standards, and collaborating with cross-functional teams to ensure high-quality and compliant clinical data outputs. Prior to joining Precision for Medicine, she held programming roles at ICON and Quintiles, where she contributed to global clinical trials across Oncology, Cardiovascular, Vaccine, and Diabetes therapeutic areas. She has led the development and validation of SDTM, ADaM, TLFs, define.xml, and submission-ready datasets for major health authorities including the FDA, PMDA, and EMEA. Beyond her expertise in SAS programming and clinical data standards, Shakila is passionate about process improvement, automation, and mentoring teams. She has recently expanded her capabilities in Data Science, gaining practical experience in Python, Machine Learning, R, and Tableau, and is keen on leveraging modern analytics and AI-driven approaches to enhance clinical research solutions., avatar=Image{width=1024,height=1536,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Shakila%20J%20Headshot.png',altText='Shakila J Headshot',fileId=219402114740}, lastname=Jagadeesan , hs_initial_published_at=1786648737451, hs_created_by_user_id=65712240, hs_created_at=1786648634345, hs_is_edited=false, hs_deleted_at=0, name=Shakila, job=Principal Statistical Programmer , slug=Shakila-Jagadeesan, hs_updated_by_user_id=92535535}, third={hs_id=219402097154, hs_child_table_id=0, hs_updated_at=1786648633237, hs_published_at=1787135938204, description=As Senior Manager of Statistical Programming, Sugumaran brings a wealth of experience to his role at Precision for Medicine, since March 2021. Prior to Precision for Medicine, he was associated with ICON Clinical Research for over 10 years across various roles in statistical programming. He has been actively involved in leading large and complex submissions for a diverse client base including large biopharma, biotech, and CROs. In addition to building his expertise in statistical programming, data analytics, and data visualization, he is deeply passionate about developing talent and cutting-edge software solutions. He is also actively involved with several social causes and CSR activities. Sugumaran holds an MBA in Pharmaceutical Management and a Master's in Bioinformatics. He is also currently pursuing a PhD in Bioinformatics., avatar=Image{width=1024,height=1536,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Sugumaran%20headshot.png',altText='Sugumaran headshot',fileId=219402130472}, lastname=Muthuraj, hs_initial_published_at=1786648737451, hs_created_by_user_id=65712240, hs_created_at=1786647962706, hs_is_edited=false, hs_deleted_at=0, name=Sugumaran, job=Senior Manager, Statistical Programming , slug=Sugumaran-Muthuraj, hs_updated_by_user_id=92535535}})
      • Zulfat K. avatar Shakila J. avatar Sugumaran M. avatar
      • Zulfat K.

        Shakila J.

        Sugumaran M.

      Discover
    • Read: Hidden Strategic Edge in Clinical Trials: Financial Project Management Hidden Strategic Edge in Clinical Trials: Financial Project Management

      Clinical Trials

      Hidden Strategic Edge in Clinical Trials: Financial Project Management

      |
        has not third author: true, (SizeLimitingPyMap: {main={hs_id=218300089344, hs_child_table_id=0, hs_updated_at=1785358312044, hs_published_at=1787135938204, description=Global Finance leader with 35+ years of progressive experience and over two decades in the global CRO industry. Proven track record of building and developing high-performing teams, leading complex financial operations, and driving strategic initiatives that improve business performance and scalability. Deep expertise in financial planning and analysis, contract negotiation, budgeting and forecasting, process optimization, auditing, cash flow management, and credit and collections. Passionate about fostering collaboration across finance, operations, and executive leadership to deliver data-driven insights, strengthen governance, and enable informed decision-making both internally and for our Sponsors., avatar=Image{width=800,height=800,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/1576750031793.jpeg',altText='1576750031793',fileId=218305569797}, lastname=Kane, hs_initial_published_at=1785358316248, hs_created_by_user_id=65712240, hs_created_at=1785358281109, hs_is_edited=false, hs_deleted_at=0, name=Romy, job=Vice President, Operational Finance, slug=romy-kane, hs_updated_by_user_id=92535535}, second={}, third={}})
      • Romy Kane avatar

        Romy Kane

      Discover
    • Read: Why Global Oncology Evidence May Not Support U.S. Regulatory Approval Why Global Oncology Evidence May Not Support U.S. Regulatory Approval

      Clinical Trials - Regulatory

      Why Global Oncology Evidence May Not Support U.S. Regulatory Approval

      |
        has not third author: true, (SizeLimitingPyMap: {main={hs_id=167363064857, hs_child_table_id=0, hs_updated_at=1719905898183, hs_published_at=1787135938204, description=Industry-leading oncologist and demonstrated medical leader in precision medicine, novel trial design and innovative regulatory initiatives designed to expedite drug approvals. Draws on nearly a decade leading oncology and rare disease programs at the FDA. Former fellow at the National Cancer Institute and frequent featured speaker at ASCO and AACR. CDER technical authority on oncologic drug and biological products for thoracic and head and neck malignancies, neurologic tumors, pediatric solid tumors and rare tumors., avatar=Image{width=553,height=580,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Harpreet-Singh2.png',altText='Harpreet-Singh2',fileId=171747124346}, linkedin=https://www.linkedin.com/in/harpreetsinghmd/, team=[{id=163072475007, name='Precision for Medicine Leadership'}], lastname=Singh, MD, hs_initial_published_at=1715692570942, hs_created_by_user_id=2737751, hs_created_at=1715692477118, hs_is_edited=false, hs_deleted_at=0, name=Harpreet, job=Chief Medical Officer, slug=harpreet-singh, hs_updated_by_user_id=92535535}, second={}, third={}})
      • Harpreet Singh, MD avatar

        Harpreet Singh, MD

      Discover
  • Translational Research Insights

    All Translational Research Articles
    • Read: Case Study: Rapid Execution of Assay Validation Rescued Global Study Case Study: Rapid Execution of Assay Validation Rescued Global Study

      Translational Research - Assays

      Case Study: Rapid Execution of Assay Validation Rescued Global Study

      |
        has not third author: true, (SizeLimitingPyMap: {main={hs_id=219184495938, hs_child_table_id=0, hs_updated_at=1786473626295, hs_published_at=1787135938204, description=Christie Bongel is a scientist by training, but her true passion lies in leadership, particularly in building leaders and shaping high-performing, trust-based cultures. She believes that many talented bench scientists are promoted into management roles without formal leadership development and is committed to helping close that gap. While culture and people development may not always appear on a balance sheet, she views them as essential drivers of long-term organizational success. As a leadership-focused operations executive, Christie leads laboratory operations and strategy within a global network, partnering with pharmaceutical and biotechnology organizations to navigate complex oncology challenges. Her work spans translational oncology, clinical trial strategy, and laboratory execution, with a focus on translating scientific and operational complexity into clear, actionable strategies that drive meaningful outcomes., avatar=Image{width=800,height=800,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/1781614819314.png',altText='Christie Bongel',fileId=219203862915}, lastname=Bongel, hs_initial_published_at=1786473638412, hs_created_by_user_id=65712240, hs_created_at=1786473568408, hs_is_edited=false, hs_deleted_at=0, name=Christie, job=Site Director, slug=christie-bongel, hs_updated_by_user_id=92535535}, second={hs_id=159488778874, hs_child_table_id=0, hs_updated_at=1765824406763, hs_published_at=1787135938204, description=Kennon Daniels is a scientific and regulatory in vitro diagnostic authority, specializing in the development of US regulatory strategies and FDA marketing submissions for IVD assays and instruments. Her expertise spans all aspects of product development, analytical and clinical trial protocol designs, Q-Submissions, IDEs, de novos, 510(k)s, and pre-market approval platforms., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Kennon%20Daniels.webp',altText='Kennon Daniels',fileId=165893120790}, linkedin=https://www.linkedin.com/in/kennon-daniels-ph-d-84a90b6, hs_name=, hs_path=, lastname=Daniels, PhD, hs_initial_published_at=1775839468505, hs_created_at=1709645745105, hs_is_edited=false, hs_deleted_at=0, name=Kennon, position=Vice President, IVD Regulatory Consulting, job=, slug=kennon-daniels, email=, hs_updated_by_user_id=92535535}, third={}})
      • Christie B. avatar

        Christie B.

      • Kennon D. avatar

        Kennon D.

      Discover
    • Read: Receptor Occupancy in the Era of Multispecific Therapeutics Receptor Occupancy in the Era of Multispecific Therapeutics

      Translational Research - Lab Services

      Receptor Occupancy in the Era of Multispecific Therapeutics

      |
        has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778875, hs_child_table_id=0, hs_updated_at=1716454216458, hs_published_at=1787135938204, description=Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Deb%20Phippard.webp',altText='Deb Phippard',fileId=165892372605}, linkedin=https://www.linkedin.com/in/deb-phippard-103b54, team=[{id=163072475007, name='Precision for Medicine Leadership'}], hs_name=, hs_path=, lastname=Phippard, PhD, hs_initial_published_at=1775839468505, hs_created_at=1709645745106, hs_is_edited=false, hs_deleted_at=0, name=Deborah, job= Chief Scientific Officer, slug=deborah-phippard, email=, hs_updated_by_user_id=92535535}, second={hs_id=218178874459, hs_child_table_id=0, hs_updated_at=1785241362455, hs_published_at=1787135938204, description=Jenny Zilberberg has more than 20 years of combined experience across academia and biotechnology, with expertise in translational immunology, cancer immunotherapy, and biomarker strategy. Most recently, she served as Head of Research at Imvax, where she led preclinical development and biomarker activities for the company’s immunotherapy platform and lead glioblastoma program. At Precision, Jenny partners with sponsors to design and implement biomarker and bioanalytical solutions that support clinical development across oncology and autoimmune diseases., avatar=Image{width=480,height=480,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/JennyZilberberg.jpeg',altText='JennyZilberberg',fileId=218182303073}, lastname=Zilberberg, hs_initial_published_at=1785241367324, hs_created_by_user_id=65712240, hs_created_at=1785241302354, hs_is_edited=false, hs_deleted_at=0, name=Jenny, job=Vice President, Scientific Strategy, slug=Jenny-zilberberg, hs_updated_by_user_id=92535535}, third={}})
      • Deborah P. avatar

        Deborah P.

      • Jenny Z. avatar

        Jenny Z.

      Discover
    • Read: Developing a Comprehensive Strategy for Implementing AI & Multi-Omics for Translational Research Developing a Comprehensive Strategy for Implementing AI & Multi-Omics for Translational Research

      Translational Research

      Developing a Comprehensive Strategy for Implementing AI & Multi-Omics for Translational Research

      |
        has not third author: true, (SizeLimitingPyMap: {main={hs_id=199448088864, hs_child_table_id=0, hs_updated_at=1762810484868, hs_published_at=1787135938204, avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Kaylee%20Mueller.png',altText='Kaylee Mueller',fileId=199456336149}, lastname=Mueller, hs_initial_published_at=1762810487482, hs_created_by_user_id=26433386, hs_created_at=1762810467146, hs_is_edited=false, hs_deleted_at=0, name=Kaylee, slug=kaylee-mueller, hs_updated_by_user_id=92535535}, second={}, third={}})
      • Kaylee Mueller avatar

        Kaylee Mueller

      Discover

All articles

  • Read: Precision Medicine in Pediatrics: Biomarkers and Assay Development Precision Medicine in Pediatrics: Biomarkers and Assay Development

    Translational Research - Biomarkers

    Precision Medicine in Pediatrics: Biomarkers and Assay Development

    |
      has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778880, hs_child_table_id=0, hs_updated_at=1714461214107, hs_published_at=1787135938204, description=Eva Raschke, PhD serves as a subject matter expert for immune monitoring solutions at Precision for Medicine with a focus on the epigenetic immune monitoring technology Epiontis ID. She has supported the development, validation and clinical use of this technology platform in different roles since 2008. Eva obtained a Ph.D. in Molecular Biology from the Ludwig-Maximilians-University Munich., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Eva%20Raschke.webp',altText='Eva Raschke',fileId=165892728972}, linkedin=https://www.linkedin.com/in/eva-raschke-678b439, hs_name=, hs_path=, lastname=Raschke, hs_initial_published_at=1775839468505, hs_created_at=1709645745111, hs_is_edited=false, hs_deleted_at=0, name=Eva, job=, slug=eva-raschke, email=, hs_updated_by_user_id=92535535}, second={}, third={}})
    • Eva Raschke avatar

      Eva Raschke

    Discover
  • Read: Conducting Pediatric Studies: Addressing Ethical and Clinical Challenges Conducting Pediatric Studies

    Clinical Trials - Translational Research - Regulatory

    Conducting Pediatric Studies: Addressing Ethical and Clinical Challenges

    |
      has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778880, hs_child_table_id=0, hs_updated_at=1714461214107, hs_published_at=1787135938204, description=Eva Raschke, PhD serves as a subject matter expert for immune monitoring solutions at Precision for Medicine with a focus on the epigenetic immune monitoring technology Epiontis ID. She has supported the development, validation and clinical use of this technology platform in different roles since 2008. Eva obtained a Ph.D. in Molecular Biology from the Ludwig-Maximilians-University Munich., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Eva%20Raschke.webp',altText='Eva Raschke',fileId=165892728972}, linkedin=https://www.linkedin.com/in/eva-raschke-678b439, hs_name=, hs_path=, lastname=Raschke, hs_initial_published_at=1775839468505, hs_created_at=1709645745111, hs_is_edited=false, hs_deleted_at=0, name=Eva, job=, slug=eva-raschke, email=, hs_updated_by_user_id=92535535}, second={}, third={}})
    • Eva Raschke avatar

      Eva Raschke

    Discover
  • Read: Methods for a Comprehensive Characterization of the Tumor Microenvironment Tumor Microenvironment

    Translational Research

    Methods for a Comprehensive Characterization of the Tumor Microenvironment

    |
      has third author: false, (SizeLimitingPyMap: {main={hs_id=159488778880, hs_child_table_id=0, hs_updated_at=1714461214107, hs_published_at=1787135938204, description=Eva Raschke, PhD serves as a subject matter expert for immune monitoring solutions at Precision for Medicine with a focus on the epigenetic immune monitoring technology Epiontis ID. She has supported the development, validation and clinical use of this technology platform in different roles since 2008. Eva obtained a Ph.D. in Molecular Biology from the Ludwig-Maximilians-University Munich., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Eva%20Raschke.webp',altText='Eva Raschke',fileId=165892728972}, linkedin=https://www.linkedin.com/in/eva-raschke-678b439, hs_name=, hs_path=, lastname=Raschke, hs_initial_published_at=1775839468505, hs_created_at=1709645745111, hs_is_edited=false, hs_deleted_at=0, name=Eva, job=, slug=eva-raschke, email=, hs_updated_by_user_id=92535535}, second={hs_id=159488778878, hs_child_table_id=0, hs_updated_at=1714461171862, hs_published_at=1787135938204, description=Jesus Garcia, PhD, is a tissue and liquid biopsy expert with extensive experience in a wide range of histopathology assays and digital pathology solutions. Part of the implementation of new technologies at MD Anderson Cancer Center in collaboration with immuno-oncology leaders. Currently focused on partnering with biopharma to develop tissue and liquid biopsy biomarker strategies for clinical trials, and to implement digital pathology and AI in the drug development process., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Jesus%20Garcia.webp',altText='Jesus Garcia',fileId=165892429965}, linkedin=https://www.linkedin.com/in/jesusgarciaphd, hs_name=, hs_path=, lastname=Garcia, hs_initial_published_at=1775839468505, hs_created_at=1709645745109, hs_is_edited=false, hs_deleted_at=0, name=Jesus, job=, slug=jesus-garcia, email=, hs_updated_by_user_id=92535535}, third={hs_id=159488778883, hs_child_table_id=0, hs_updated_at=1762803857448, hs_published_at=1787135938204, description=Jie Yang, PhD is a Scientific Liaison for Precision for Medicine. An Immunologist by training with extensive industry expertise in designing translational assays for biomarker-guided clinical trials. Conducted postdoctoral research on immuno-oncology at MD Anderson Cancer Center. Led biomarker assay development and collaborated on the implementation of new technologies for pre-clinical and clinical studies conducted by pharmaceutical and biotech companies for drug development., avatar=Image{width=885,height=886,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Jie-Yang.png',altText='Jie-Yang',fileId=167372215352}, linkedin=https://www.linkedin.com/in/jie-yang-0528221b, hs_name=, hs_path=, lastname=Yang, PhD, hs_initial_published_at=1775839468505, hs_created_at=1709645745114, hs_is_edited=false, hs_deleted_at=0, name=Jie, job=, slug=jie-yang, email=, hs_updated_by_user_id=92535535}})
    • Eva R. avatar Jesus G. avatar Jie Y. avatar
    • Eva R.

      Jesus G.

      Jie Y.

    Discover
  • Read: Characterizing a Central Switch of Immune Suppression: Monitoring Treg Cells in Clinical Studies Immune Suppression

    Translational Research

    Characterizing a Central Switch of Immune Suppression: Monitoring Treg Cells in Clinical Studies

    |
      has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778880, hs_child_table_id=0, hs_updated_at=1714461214107, hs_published_at=1787135938204, description=Eva Raschke, PhD serves as a subject matter expert for immune monitoring solutions at Precision for Medicine with a focus on the epigenetic immune monitoring technology Epiontis ID. She has supported the development, validation and clinical use of this technology platform in different roles since 2008. Eva obtained a Ph.D. in Molecular Biology from the Ludwig-Maximilians-University Munich., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Eva%20Raschke.webp',altText='Eva Raschke',fileId=165892728972}, linkedin=https://www.linkedin.com/in/eva-raschke-678b439, hs_name=, hs_path=, lastname=Raschke, hs_initial_published_at=1775839468505, hs_created_at=1709645745111, hs_is_edited=false, hs_deleted_at=0, name=Eva, job=, slug=eva-raschke, email=, hs_updated_by_user_id=92535535}, second={}, third={}})
    • Eva Raschke avatar

      Eva Raschke

    Discover
  • Read: Using Epigenetic Immunophenotyping to Explore Potential Biomarkers in Hepatocellular Carcinoma Using Epigenetic Immunophenotyping to Explore Potential Biomarkers in Hepatocellular Carcinoma

    Translational Research

    Using Epigenetic Immunophenotyping to Explore Potential Biomarkers in Hepatocellular Carcinoma

    |
      has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778880, hs_child_table_id=0, hs_updated_at=1714461214107, hs_published_at=1787135938204, description=Eva Raschke, PhD serves as a subject matter expert for immune monitoring solutions at Precision for Medicine with a focus on the epigenetic immune monitoring technology Epiontis ID. She has supported the development, validation and clinical use of this technology platform in different roles since 2008. Eva obtained a Ph.D. in Molecular Biology from the Ludwig-Maximilians-University Munich., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Eva%20Raschke.webp',altText='Eva Raschke',fileId=165892728972}, linkedin=https://www.linkedin.com/in/eva-raschke-678b439, hs_name=, hs_path=, lastname=Raschke, hs_initial_published_at=1775839468505, hs_created_at=1709645745111, hs_is_edited=false, hs_deleted_at=0, name=Eva, job=, slug=eva-raschke, email=, hs_updated_by_user_id=92535535}, second={}, third={}})
    • Eva Raschke avatar

      Eva Raschke

    Discover
  • Read: Non-Invasive Immune Monitoring to Predict COVID-19 Disease Course and Assess SARS-CoV-2 Vaccine Response Non-Invasive Immune Monitoring to Predict COVID-19 Disease Course and Assess SARS-CoV-2 Vaccine Response

    Translational Research

    Non-Invasive Immune Monitoring to Predict COVID-19 Disease Course and Assess SARS-CoV-2 Vaccine Response

    |
      has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778880, hs_child_table_id=0, hs_updated_at=1714461214107, hs_published_at=1787135938204, description=Eva Raschke, PhD serves as a subject matter expert for immune monitoring solutions at Precision for Medicine with a focus on the epigenetic immune monitoring technology Epiontis ID. She has supported the development, validation and clinical use of this technology platform in different roles since 2008. Eva obtained a Ph.D. in Molecular Biology from the Ludwig-Maximilians-University Munich., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Eva%20Raschke.webp',altText='Eva Raschke',fileId=165892728972}, linkedin=https://www.linkedin.com/in/eva-raschke-678b439, hs_name=, hs_path=, lastname=Raschke, hs_initial_published_at=1775839468505, hs_created_at=1709645745111, hs_is_edited=false, hs_deleted_at=0, name=Eva, job=, slug=eva-raschke, email=, hs_updated_by_user_id=92535535}, second={}, third={}})
    • Eva Raschke avatar

      Eva Raschke

    Discover
  • Read: Next-Generation Immune Monitoring in Immuno-oncology Trials Next-Generation Immune Monitoring in Immuno-oncology Trials

    Translational Research

    Next-Generation Immune Monitoring in Immuno-oncology Trials

    |
      has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778880, hs_child_table_id=0, hs_updated_at=1714461214107, hs_published_at=1787135938204, description=Eva Raschke, PhD serves as a subject matter expert for immune monitoring solutions at Precision for Medicine with a focus on the epigenetic immune monitoring technology Epiontis ID. She has supported the development, validation and clinical use of this technology platform in different roles since 2008. Eva obtained a Ph.D. in Molecular Biology from the Ludwig-Maximilians-University Munich., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Eva%20Raschke.webp',altText='Eva Raschke',fileId=165892728972}, linkedin=https://www.linkedin.com/in/eva-raschke-678b439, hs_name=, hs_path=, lastname=Raschke, hs_initial_published_at=1775839468505, hs_created_at=1709645745111, hs_is_edited=false, hs_deleted_at=0, name=Eva, job=, slug=eva-raschke, email=, hs_updated_by_user_id=92535535}, second={hs_id=159488778885, hs_child_table_id=0, hs_updated_at=1714461091541, hs_published_at=1787135938204, description=Dr. Hoffmueller is a veteran biochemist, industry expert, and cofounder of Epiontis. He holds a Master’s in Biochemistry from Humboldt University, a PhD from the Charité University Clinic, receiving the Charité Research Award, and an MBA from the Berlin School of Economics and Law, Berlin, Germany., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Ulrich%20Hoffmueller.webp',altText='Ulrich Hoffmueller',fileId=165891429692}, linkedin=https://www.linkedin.com/in/hoffmueller, hs_name=, hs_path=, lastname=Hoffmueller, hs_initial_published_at=1775839468505, hs_created_at=1709645745116, hs_is_edited=false, hs_deleted_at=0, name=Ulrich, job=, slug=ulrich-hoffmueller, email=, hs_updated_by_user_id=92535535}, third={}})
    • Eva R. avatar

      Eva R.

    • Ulrich H. avatar

      Ulrich H.

    Discover
Loading...
You've reach the end